Since 1999, MHRP has worked with local collaborators to advance research into an effective HIV vaccine and promote HIV prevention. Research is conducted in partnership with the National Institute of Medical Research, the University of Munich (LMU), the Mbeya Regional Medical Office, and the Mbeya Referral Hospital. Together, these collaborating institutions form the Mbeya Medical Research Center (MMRC).
In 2014, the site was selected as a part of MHRP’s Clinical Trial Unit to receive funding from the National Institute of Allergy and Infectious Diseases (NIAID) to join the HIV Vaccine Trials Network (HVTN) and conduct research. In 2016, the site began HVTN 703 (AMP Study), a Phase I study testing broad and potent monoclonal antibody (bNAb) VRC01 for HIV prevention. This site will also take part in HVTN vaccine research trials that build upon the success of the RV144 HIV vaccine trial, which was led by MHRP in Thailand.
Ongoing research studies:
• RV217 (ECHO): HIV-1 Prevalence, Incidence, Cohort Retention, and Host Genetics and Viral Diversity in High Risk Cohorts in East Africa
• Infectious Disease Surveillance (HIV, TB and Malaria) and Cohort Development Among Urban and Rural Communities
• Karolinska Institute vaccine study in Tanzania testing a prime-boost HIV vaccine regimen using unadjuvanted DNA vaccines followed by a Modified Vaccinia Ankara (MVA), which was developed by MHRP and NIAID. This HIV vaccine research study is being conducted in collaboration with Muhimbili University (MUHAS).
Research activities are supported by an active Community Advisory Board (CAB), which was created in 2005 as part of an effort to facilitate dialogue between community members, study volunteers and the research team.